In diabetic patients, Everolimus eluting stents could perform better than Paclitaxel eluting stents

Original title: Safety and Efficacy of Everolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in a Diabetic Population Reference: Ana Laynez et, al. Catheterization and Cardiovascular Intervention 81:759-765 (2013) Everolimus eluting stents have already been compared with paclitaxel eluting stents in the general population, and they have proved to perform best, especially as regards revascularization and in-stent thrombosis.  However, these data<a href="https://solaci.org/en/2013/04/09/n-2836/" title="Read more" >...</a>

Paclitaxel eluting balloon in the femoropopliteal region

Original title: Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. A Meta-Analysis of Randomized Trials. Reference: Salvatore Cassese et al. Circ Cardiovasc Interv. 2012;5:582-589. Balloon angioplasty is one of the most frequent alternatives used in patients with peripheral vascular disease, especially in the femoropopliteal region.  However, its effectiveness is reduced in<a href="https://solaci.org/en/2013/03/27/n-2997/" title="Read more" >...</a>

The use of a paclitaxel eluting balloon in small vessels

Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020 The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. <a href="https://solaci.org/en/2012/11/16/n-3774/" title="Read more" >...</a>

AGENT-IDE: Drug Coated Balloons for Instent Restenosis

Drug eluting stents (DES) have improved considerably over the years, reducing the initial indices of instent restenosis (ISR) by roughly 5-10% a year in USA. However, DES failure might lead to neointimal hyperplasia and neoatherosclerosis, which increases the chance of developing chronic and acute coronary syndromes.  Drug coated balloons (DCB), which administer anti-proliferative agents with<a href="https://solaci.org/en/2024/03/21/agent-ide-drug-coated-balloons-for-instent-restenosis/" title="Read more" >...</a>

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

IN.PACT Outcomes at 5 Years

Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than conventional PCI. However, in many cases, stenting is required to treat suboptimal results.  Even though several studies have looked into this scenario, long term durability still calls for research. This was a 5 year thorough analysis of the<a href="https://solaci.org/en/2024/03/09/in-pact-outcomes-at-5-years/" title="Read more" >...</a>

Acceso retrógrado mediante la arteria tibial para el tratamiento de oclusiones en territorio femoropoplíteo: ¿es una estrategia segura?

Treatment of Femoropopliteal Lesions with Low-Dose vs. High-Dose Drug-Coated Balloons

The use of drug-covered balloons (DCBs) has increased significantly for the endovascular treatment of femoropopliteal arterial disease. Previous studies on first-generation high-dose DCB (HD-DCB) have validated its benefits, thus supporting its recommendation in current clinical guidelines. However, there have been reports of adverse effects associated with paclitaxel and its excipients. Second-generation, lower-dose DCBs (LD-DCB) have<a href="https://solaci.org/en/2024/03/01/treatment-of-femoropopliteal-lesions-with-low-dose-vs-high-dose-drug-coated-balloons/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and<a href="https://solaci.org/en/2024/02/22/recurrent-revascularization-at-10-years-after-percutaneous-treatment-of-des-in-stent-restenosis/" title="Read more" >...</a>

Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions

Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this strategy have shown clinical outcomes comparable to drug-eluting stents’ (DES) in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCB in large coronary vessels is limited. This observational, retrospective study DCB<a href="https://solaci.org/en/2023/12/21/outcomes-of-the-use-of-drug-coated-balloons-in-the-treatment-of-de-novo-coronary-lesions/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Low Gradient, Normal Flow Aortic Stenosis: Changes in Quality of Life with TAVR

There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity<a href="https://solaci.org/en/2023/11/30/low-gradient-normal-flow-aortic-stenosis-changes-in-quality-of-life-with-tavr/" title="Read more" >...</a>

¿Es la litotricia coronaria tan efectiva como la aterectomía rotacional?

ROTACUT Study: Rotational Atherectomy with Cutting Balloon for Stent Expansion Optimization

Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents a significant challenge involving a high incidence of major adverse cardiovascular events (MACE). Rotational atherectomy (RA) is used to modify these calcified lesions and facilitate balloon angioplasty followed by stent implantation. The combination of RA with other plaque<a href="https://solaci.org/en/2023/11/30/rotacut-study-rotational-atherectomy-with-cutting-balloon-for-stent-expansion-optimization/" title="Read more" >...</a>